Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037170 | 0.76 | AR (0.54) | CYP19A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL342680 | 0.73 | ABCB1 (0.42) | ABCB1ABCG2 | |
| SCHEMBL1923495 | 0.70 | AR (0.43) | CYP19A1LMNASMN1; SMN2ALDH1A1F2 | |
| SCHEMBL793294 | 0.69 | CYP19A1 (0.31) | CYP19A1ABCB1SCN9A | |
| SCHEMBL873803 | 0.67 | TUBB1 (0.40) | ABCB1ABCG2 | |
| SCHEMBL1829320 | 0.65 | TTR (0.42) | CYP19A1MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11838721 | 0.64 | CA2 (0.61) | MAPTKDM4EALDH1A1MAPK1TSHR | |
| SCHEMBL31435284 | 0.63 | PTGS2 (0.48) | CYP19A1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL23525664 | 0.62 | HTT (0.38) | LMNAMAPTSMN1; SMN2KDM4EUSP2 | |
| SCHEMBL1829321 | 0.62 | NPC1 (0.47) | CYP3A4MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-3661945-B1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | ARDELYX, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-4234016-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20050186198-A1 | Serine protease inhibitors | GENENTECH, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6919369-B2 | Controlling blood coagulation | GENENTECH, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040242585-A1 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040235852-A1 | Benzofuran inhibitors of factor VIIa | GENENTECH, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040235750-A1 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040158076-A1 | Tyrosine derivatives | GENENTECH, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040110753-A1 | Tyrosine derivatives | GENENTECH, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030212071-A1 | Serine protease inhibitors | GENENTECH, INC. | 2003-11-13 | — | — | US | disclosed |
| US-6472393-B1 | Serine protease inhibitors | GENENTECH, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6469047-B1 | NON-PROTEIN SMALL MOLECULE COMPOUNDS WHICH INHIBIT THE INTERACTION BETWEEN THE ALPHA 4 BETA 7 INTEGRIN AND ITS LIGANDS MADCAM AND/OR VCAM. THESE COMPOUNDS ARE USEFUL FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SUCH AS ARTHRITIS | GENENTECH, INC. | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212071-A1 | Serine protease inhibitors | SERPINE1, SPINT2, TFPI | CYP19A1 1100/4885LMNA 908/4885MAPT 4012/4885 |
| US-20050186198-A1 | Serine protease inhibitors | TFPI, SPINT2, SERPINE1 | CYP19A1 1209/4885LMNA 831/4885MAPT 3882/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | CYP19A1 1227/4885LMNA 1098/4885MAPT 3747/4885 |
| US-20040235750-A1 | Thiocarbamate inhibitors of alpha-4 integrins | ITGB4, ITGA4, ITGB1 | CYP19A1 3958/4885LMNA 2603/4885MAPT 2546/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP19A1 3751/4885LMNA 3716/4885MAPT 3822/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP19A1 3863/4885LMNA 3718/4885MAPT 3696/4885 |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | HSD11B2, HSD11B1, HSD3B2 | CYP19A1 79/4885LMNA 2542/4885MAPT 3787/4885 |
| US-20040235852-A1 | Benzofuran inhibitors of factor VIIa | TFPI, HABP2, SERPINE1 | CYP19A1 120/4885LMNA 1022/4885MAPT 4422/4885 |
| US-20040242585-A1 | Acylsulfamide inhibitors of factor VIIa | TFPI, TFPI2, HABP2 | CYP19A1 441/4885LMNA 1391/4885MAPT 4778/4885 |
| US-20040110753-A1 | Tyrosine derivatives | VCAM1, ICAM1, ITGB4 | CYP19A1 4206/4885LMNA 4385/4885MAPT 2057/4885 |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | GRHPR, REN, GRK5 | CYP19A1 778/4885LMNA 2166/4885MAPT 3352/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | CYP19A1 107/4885LMNA 3455/4885MAPT 3972/4885 |
| US-20040158076-A1 | Tyrosine derivatives | VCAM1, ICAM1, ITGB4 | CYP19A1 4206/4885LMNA 4385/4885MAPT 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.